[go: up one dir, main page]

MX2024003130A - Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma. - Google Patents

Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma.

Info

Publication number
MX2024003130A
MX2024003130A MX2024003130A MX2024003130A MX2024003130A MX 2024003130 A MX2024003130 A MX 2024003130A MX 2024003130 A MX2024003130 A MX 2024003130A MX 2024003130 A MX2024003130 A MX 2024003130A MX 2024003130 A MX2024003130 A MX 2024003130A
Authority
MX
Mexico
Prior art keywords
dihydro
substituted
naphthyridine
amide
naphthyridine amide
Prior art date
Application number
MX2024003130A
Other languages
English (en)
Inventor
Zhen Zhang
Jian Yu
Yang Yang
Lin Ding
Yunfei Li
Xiaoyan Lin
Original Assignee
Tuojie Biotech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuojie Biotech Shanghai Co Ltd filed Critical Tuojie Biotech Shanghai Co Ltd
Publication of MX2024003130A publication Critical patent/MX2024003130A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención refiere a una amida de 1,4-dihidro-1,6-nafti ridina sustituida y su uso. Específicamente, se proporciona un compuesto representado por la fórmula I o una sal farmacéuticamente aceptable del mismo, donde R1, R3-R11, Z1 y Z2 se definen de acuerdo con la presente invención. (ver Fórmula).
MX2024003130A 2021-09-18 2022-09-16 Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma. MX2024003130A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202111104458 2021-09-18
CN202111324281 2021-11-10
CN202111636982 2021-12-29
PCT/CN2022/119209 WO2023041004A1 (zh) 2021-09-18 2022-09-16 取代的1,4-二氢-1,6-萘啶酰胺及其用途

Publications (1)

Publication Number Publication Date
MX2024003130A true MX2024003130A (es) 2024-04-10

Family

ID=85602452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003130A MX2024003130A (es) 2021-09-18 2022-09-16 Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma.

Country Status (10)

Country Link
US (1) US20240376101A1 (es)
EP (1) EP4403555A4 (es)
JP (1) JP2024535804A (es)
KR (1) KR20240068057A (es)
CN (1) CN117836295A (es)
AU (1) AU2022348784A1 (es)
CA (1) CA3231311A1 (es)
MX (1) MX2024003130A (es)
TW (1) TW202328127A (es)
WO (1) WO2023041004A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4541794A1 (en) * 2022-07-29 2025-04-23 Suzhong Pharmaceutical Group Co., Ltd. Phenyl-substituted dihydronaphthyridine compounds, and preparation and use thereof
EP4682147A1 (en) * 2023-03-17 2026-01-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystal form of 1,4-dihydro-1,6-naphthyridine amide compound and preparation method therefor
CN119306715A (zh) * 2023-07-11 2025-01-14 苏中药业集团股份有限公司 苯基取代的二氢萘啶类化合物的晶体及其用途
TWI888920B (zh) * 2023-09-18 2025-07-01 大陸商蘇中藥業集團股份有限公司 苯基取代的二氫萘啶類化合物及其製備與用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006026585A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
AU2019272300B2 (en) 2018-05-22 2024-07-25 Sunshine Lake Pharma Co., Ltd. Phenyl-substituted dihydronaphthyridine compound and use thereof
CN113214248B (zh) * 2021-04-13 2022-04-26 湖南南新制药股份有限公司 一种1,4-二氢-1,6-萘啶衍生物、药物组合物及其用途

Also Published As

Publication number Publication date
CN117836295A (zh) 2024-04-05
TW202328127A (zh) 2023-07-16
EP4403555A1 (en) 2024-07-24
JP2024535804A (ja) 2024-10-02
AU2022348784A1 (en) 2024-04-04
KR20240068057A (ko) 2024-05-17
EP4403555A4 (en) 2025-01-22
US20240376101A1 (en) 2024-11-14
CA3231311A1 (en) 2023-03-23
WO2023041004A1 (zh) 2023-03-23

Similar Documents

Publication Publication Date Title
MX2024003130A (es) Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma.
CO2023015419A2 (es) Compuesto de péptido corto de prolina modificado con anillo y uso del mismo
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
MX2024008987A (es) Derivado de heteroaril-pireno sustituido por anillo puenteado, y uso del mismo.
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX2025011216A (es) Compuesto de pirimidopirano sustituido con heterocíclico y uso del mismo
AR115949A1 (es) Compuestos heterocíclicos
CO2023000396A2 (es) Nuevo inhibidor de la secreción de ácido y uso del mismo
MX2023009037A (es) Compuesto de pirimidopirano.
MX2024012930A (es) Derivado de ester de ciclopentanol sustituido con pirazol y uso del mismo
UY27577A1 (es) Inhibidores de la integrasa del vih
MX2020013852A (es) Derivados de tetrahidrotienopiridina n-sustituidos y sus usos.
DOP2024000077A (es) Compuestos de cd73
DOP2011000154A (es) 3-aminociclopentancarboxamidas
CO2022004391A2 (es) Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4
MX2023015440A (es) Compuesto de sulfoximina y uso del mismo.
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
MX2022002720A (es) Inhibidor de magl, procedimiento de preparacion y uso del mismo.
AR133855A1 (es) Compuestos de amina sustituida, composiciones y métodos de uso
AR132661A1 (es) Quinoxalinas substituidas
CR20240570A (es) Compuestos de cd73
AR108363A1 (es) Compuestos de tetrahidrofurooxazina y su uso como inhibidores de bace1 selectivos